Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio

Core Viewpoint - Silo Pharma, Inc. has received a patent for its lead asset SPC-15, which is an intranasal treatment for post-traumatic stress disorder (PTSD), enhancing its intellectual property portfolio and supporting clinical trial development plans [1][2][3]. Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [4]. - The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis [4]. Product Details - SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders like PTSD and anxiety [3]. - The product has potential eligibility for the FDA's streamlined 505(b)(2) regulatory pathway, which could accelerate its approval process [3]. - Silo Pharma collaborates with Columbia University for preclinical studies and holds exclusive global rights for the development and commercialization of SPC-15 [3].